Crinetics Pharmaceuticals, Inc. (CRNX)

USD 52.09

(-5.92%)

Market Cap (In USD)

4.83 Billion

Revenue (In USD)

4.01 Million

Net Income (In USD)

-214.52 Million

Avg. Volume

725.1 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
33.67-62.53
PE
-
EPS
-
Beta Value
0.619
ISIN
US22663K1079
CUSIP
22663K107
CIK
1658247
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. R. Scott Struthers Ph.D.
Employee Count
-
Website
https://www.crinetics.com
Ipo Date
2018-07-18
Details
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.